/ /

  • linkedin
  • Increase Font
  • Sharebar

    Novel glaucoma drugs close at hand

    Agents act on prostaglandin receptors; some combine this with other mechanisms of action

     

    In other phase I and II trials, he found:

    • ONO 9054 (Santen), an ONO compound that is an agonist of two prostaglandin receptors (EP3 and FP) receptor agonist)
    • A growth factor NT-501 (CNTF) being studied at Stanford
    • DE-177 (Santen), a selective EP2 receptor agonist
    • GL-101 (Glia)
    • Salvum

    Dr. Novack noted he was not able to find much information about the last two.

    None of the drugs on the horizon provides neuroprotection, he said, pointing out the difficult regulatory hurdles for such a drug to clear.

    “So, Gary, where are the rest?” he asked, anticipating his audience’s question. “That’s as many as I could find.”

    It takes about 10 years from invention of a molecule to its approval, he said. The past 3 to 4 years of that time span are the phase III studies and the approval.

    “By definition if something is not in phase III now it’s going to be at least 4 years before it’s available to you and your patients,” he said.

    The problem is not a lack of good ideas. Rather, Dr. Novack believes complex financial incentives are in play.

    Still, glaucoma physicians should not give up hope of improving patient care, he noted.

    As Millennials take over from baby boomers in drug development, they may bring new approaches, he added.

    “I think they’d take a drug reservoir, have a computer-controlled release of that drug, measure efficacy however you want—IOP, visual fields—then have a feedback on the release of the drug, probably through a phone app,” he said.

    Another rho kinase inhibitor, ripasudil 0.4% (Glanatec, Kowa), received approval in Japan in 2014. Gene therapy is also being researched.

     

    Gary D. Novack, PhD
    e: [email protected]
    This article was adapted from Dr. Novack’s presentation at the 2017 meeting of the American Academy of Ophthalmology. Dr. Novack disclosed financial relationships with Achillion, Aerie, Aldeyra, Allergan, Allysta, Aurinia, Chengdu Kanghong, CloudBreak, CoDa, CXLO, DSM, Envisia, Eximore, Graybug, JCyte, Kala, Lexitas, Lung, Ocugenix, Panoptica, Peregrine, Qooqoo, SunPharma, Sylentis, Tyrogenex, and Viewpoint.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results